Recently, LY2109761, a TGF-b receptor inhibitor, was increasingly confirmed to serve as suppressor of the synthesis and release of connective tissue growth factor in tumor environment, which in turn reduced tumor cell growth, intravasation, and metastatic dissemination of HCC cells through different molecular mechanisms [22, 23]. This evidence concerns the gene CCN2 and neoplasm.